Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: Summary statement of a First National Institutes of Health/Office of Rare Diseases conference
Researchers and clinicians with expertise in autosomal recessive polycystic kidney disease and congenital hepatic fibrosis (ARPKD/CHF) and related fields met on May 5-6, 2005, on the National Institutes of Health (NIH) campus for a 1.5-day symposium sponsored by the NIH Office of Rare Diseases, the National Human Genome Research Institute (NHGRI), and in part by the ARPKD/CHF Alliance. The meeting addressed the present status and the future of ARPKD/CHF research.
Abbreviations: ACE, Angiotensin converting enzyme , ADPKD, Autosomal dominant polycystic kidney disease , ARB, Angiotensin II receptor blocker , ARPKD/CHF, Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis , cAMP, Cyclic adenosine monophosphate , CHF, Congenital hepatic fibrosis , DHPLC, Denaturing high-performance liquid chromatography , EGF, Epidermal growth factor , NHGRI, National Human Genome Research Institute , NIH, National Institutes of Health , PKD, Polycystic kidney disease , QTL, Quantitative trait locus
To access this article, please choose from the options below
Supported in part by the Intramural Research Program of the NIH, specifically, that of the National Human Genome Research Institute, and by the Office of Rare Diseases, Office of the Director, NIH, and ARPKD/CHF Alliance.
PII: S0022-3476(06)00186-7
doi:10.1016/j.jpeds.2006.03.014
© 2006 Mosby, Inc. All rights reserved.
